Quantcast

Latest Sham surgery Stories

2014-07-21 10:19:04

North Shore-Long Island Jewish (LIJ) Health System The brain network measures placebo effects in Parkinson's disease patients Investigators at The Feinstein Institute for Medical Research have utilized a new image-based strategy to identify and measure placebo effects in randomized clinical trials for brain disorders. The findings are published in the August issue of The Journal of Clinical Investigation. Parkinson's disease is the second most common neurodegenerative disease in the...

2012-03-14 20:54:13

A scale developed to measure the potential harm caused by invasive placebos in local anaesthesia research has been successfully tested by a group of 43 independent clinicians. The consultant anaesthetists were asked to assess the risk of harm posed by control group interventions described in ten published clinical anaesthesia studies using the Serious Harm and Morbidity (SHAM) scale. There was substantial agreement between the 22 consultants who were given clinical examples to...

2011-06-08 13:45:00

FORT LEE, N.J., June 8, 2011 /PRNewswire/ -- Neurologix, Inc. (OTCBB: NRGX) announced today several new results from the Company's successful Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) as part of a comprehensive presentation of study findings to the National Institutes of Health (NIH) Recombinant DNA Advisory Committee (RAC). Recently completed analysis of new data showed patients treated with NLX-P101 had...

2011-03-17 12:37:22

A multi-center gene therapy trial for patients with advanced Parkinson's disease demonstrated reduced symptoms of the progressive movement disorder, according to a new study published in Lancet Neurology. The study was designed to deliver the gene for glumatic acid decarboxylase (GAD) packaged in inert viral vectors into an area of the brain called the subthalamic nucleus. GAD makes an important inhibitory chemical called GABA. The subthalamic nucleus is abnormally activated in Parkinson's...

2011-03-17 12:34:36

A first-of-its-kind study of gene therapy in the treatment of Parkinson's disease determined that half of all patients who received the treatment had "clinically meaningful improvements" of their symptoms within six months of surgery. "The study demonstrates that the promise of gene therapy for neurodegenerative disorders has become a reality," says study lead author and co-principal investigator Peter LeWitt, M.D., director of movement disorders at Henry Ford Health System. The new study is...

2011-03-17 12:32:49

Results from the first successful phase 2 clinical trial of gene therapy for Parkinson's or any neurologic disorder A gene therapy called NLX-P101 dramatically reduces movement impairment in Parkinson's patients, according to results of a Phase 2 study published today in the journal Lancet Neurology. The approach introduces a gene into the brain to normalize chemical signaling. The study is the first successful randomized, double-blind clinical trial of a gene therapy for Parkinson's or any...

2011-03-16 17:30:00

FORT LEE, N.J., March 16, 2011 /PRNewswire/ -- Neurologix, Inc. (OTC Bulletin Board: NRGX), announced today that the results of the Company's Phase 2 clinical trial for its novel, investigational gene therapy NLX-P101 for the treatment of Parkinson's disease (PD) were published in an online-first edition of The Lancet Neurology. The randomized, double-blind, sham surgery-controlled trial of 45 subjects with advanced PD met its primary outcome measurement for efficacy and demonstrated that...

2011-02-03 08:00:00

SAN DIEGO, Feb. 3, 2011 /PRNewswire/ -- Ceregene, Inc., a biopharmaceutical company, announced today that it is progressing with enrollment and dosing in its CERE-120 (AAV2-neurturin) Phase 2b multi-center, sham-surgery, double-blinded controlled trial in Parkinson's disease. This trial was initiated in October 2010 and all 11 centers across the United States are now actively enrolling patients. These sites are among the best movement disorders centers in the country and include Baylor...

2008-08-19 12:01:01

Neurologix has received institutional review board approvals to begin recruiting and enrolling participants for its Phase II clinical trial of the company's gene transfer approach to the treatment of advanced Parkinson's disease. The study is designed to evaluate the safety and efficacy of a novel non-dopaminergic approach for reestablishing motor function in Parkinson's patients who are sub-optimally responsive to drug therapies. The randomized, double-blind, sham-procedure controlled...

2008-07-02 09:01:03

Titan Pharmaceuticals, Inc. (AMEX:TTP) today announced initial analyses show that Spheramine(R) did not meet the Phase IIb clinical study's primary or key secondary endpoints, with no significant differences detected between the Spheramine and sham surgery arms of the study after 12 months of follow-up. The Phase IIb trial was designed to explore the safety, tolerability and efficacy of Spheramine, the company's novel cell-based therapy for the potential treatment of moderate to advanced...


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related